Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3848851 | 0.80 | SLC6A9 (0.71) | SLC6A9ALDH1A1LMNA | |
| SCHEMBL3850083 | 0.76 | SLC6A9 (0.69) | SLC6A9ALDH1A1LMNA | |
| SCHEMBL3858444 | 0.75 | SLC6A9 (0.62) | SLC6A9ALDH1A1 | |
| SCHEMBL3858701 | 0.72 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL3848872 | 0.71 | SLC6A9 (0.61) | SLC6A9ALDH1A1LMNA | |
| SCHEMBL3850161 | 0.71 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL6277369 | 0.66 | ALDH1A1 (0.56) | SLC6A9ALDH1A1LMNA | |
| SCHEMBL6288006 | 0.66 | SMN1; SMN2 (0.60) | LMNAMAPK10SMN1; SMN2FBP1 | |
| SCHEMBL3575069 | 0.65 | ATG4B (0.48) | LMNASMN1; SMN2FBP1 | |
| SCHEMBL3848705 | 0.64 | SLC6A9 (0.90) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576083-B2 | Morpholinyl piperidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576083-B2 | Morpholinyl piperidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576083-B2 | Morpholinyl piperidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2005107469-A2 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | SLC1A1, SLC1A2, SLC6A7 | SLC6A9 30/4885ALDH1A1 2358/4885LMNA 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.